Crisaborole
- Generic Name
- Crisaborole
- Brand Names
- Eucrisa
- Drug Type
- Small Molecule
- Chemical Formula
- C14H10BNO3
- CAS Number
- 906673-24-3
- Unique Ingredient Identifier
- Q2R47HGR7P
- Background
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. It is currently under development as topical treatment of psoriasis.
- Indication
Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
- Associated Conditions
- Mild Atopic dermatitis, Moderate Atopic dermatitis
- Associated Therapies
- -
Drug giants display advanced technologies, solutions at CIIE
Global Dermatology Drugs Market to Worth Over US$ 50.42
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.